Published • loading... • Updated
Roche Strikes Obesity Drug Licensing Deal Worth up to $1.16 Billion with Chinese Rona Therapeutics
Rona will receive $100 million upfront and up to $1.06 billion more in milestones and royalties as Roche seeks a foothold in obesity drugs.
10 Articles
10 Articles
With the partnership, the pharmaceutical group secures a worldwide license for active ingredients against obesity. This pushes Roche further to the lucrative market for weight loss preparations.
·Düsseldorf, Germany
Read Full Article
PR NewswireReposted by 
The Queenslander
The QueenslanderRona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
/PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational...
·Chicago, United States
Read Full Article
Roche’s China shopping spree continues with $1B Rona obesity pact - European Biotechnology Magazine
Roche has licensed worldwide rights to Rona Therapeutics’ experimental ALK7-targeting RNA interference therapy for obesity and metabolic diseases, offering up to $100 million (about €89 million) in upfront and near-term payments, plus up to $1.06 billion (about €0.95 billion) in milestone payments.
Coverage Details
Total News Sources10
Leaning Left1Leaning Right3Center3Last UpdatedBias Distribution43% Center, 43% Right
Bias Distribution
- 43% of the sources are Center, 43% of the sources lean Right
43% Right
14%
C 43%
R 43%
Factuality
To view factuality data please Upgrade to Premium
